Personalized cortical tES restores memory-network function in Alzheimer’s disease
PrimaryBottneuro’s core causal theory is that non-invasive transcranial electrical stimulation can therapeutically modulate cortical brain networks whose dysfunction contributes to cognitive impairment in Alzheimer’s disease and related cognitive disorders. The supplied publication material specifically identifies the left angular gyrus as a stimulation target relevant to restoring memory functions impaired by Alzheimer’s disease, and notes interest in stimulating network nodes such as the default mode network. A testable prediction is that patients receiving personalized active stimulation of these cortical targets should show greater target engagement and, in clinical settings, better cognitive or disease-relevant outcomes than sham-stimulated patients or patients receiving non-personalized stimulation.
Popperian evaluation
The mechanistic premise is credible at the hardware and field-modeling level: individual anatomy changes delivered electric fields, and MRI-informed personalized montages can improve modeled target engagement. The leap is clinical. The evidence here does not yet show that stimulating the left angular gyrus or default-mode-network nodes restores memory-network function in Alzheimer’s patients.
Supporting evidence: Conventional tES montages produce highly variable electric fields across subjects because anatomy differs.; A 2025 NeuroImage modeling study in 10 healthy subjects found that flexible personalized electrode positioning improved target engagement and reduced target-intensity variance.; The left angular gyrus is a plausible memory-network stimulation target in the supplied material.
Counter evidence: The central Alzheimer’s efficacy premise rests on an assumption with low confidence: modulating cortical memory-network nodes improves cognitive or disease-relevant outcomes.; The strongest target-engagement evidence is in silico and used healthy subjects, not Alzheimer’s patients.; Feasibility data for the cap system came from eight healthy subjects, which says little about disease biology.
The theory explains why personalized caps might deliver a cleaner electrical dose to a chosen cortical target. It does not yet explain Alzheimer’s cognitive outcomes, because the supplied evidence stops before patient-level biomarker, network, or clinical response data. Our hypothesis is that personalization may solve part of the dose-delivery problem, while the disease-modification claim remains unproven.
Supporting evidence: Personalized optimization reduced modeled variance of stimulation intensity in the target compared with reference-model optimization.; Increasing available electrode positions from 32 to about 86 improved target engagement across target intensities and current limits in simulations.; Patient-specific 3D-printed caps are designed to reduce placement error during repeat tES and EEG sessions.
Counter evidence: Alternative explanations can account for the current evidence: better anatomical fit, more electrode choices, and more precise placement can improve modeled fields without changing Alzheimer’s biology.; No supplied publication shows that target engagement caused memory-network normalization in Alzheimer’s patients.; No supplied publication shows better cognition or disease-relevant outcomes against sham stimulation.
The theory makes testable claims. A randomized trial could compare personalized active stimulation with sham and non-personalized stimulation, then measure target engagement, EEG or imaging network effects, cognition, and disease-relevant endpoints. If personalized stimulation improves modeled dose but fails to change network or clinical outcomes, the therapeutic version of the theory takes a direct hit.
Supporting evidence: The stated prediction compares personalized active stimulation against sham stimulation and non-personalized stimulation.; Target engagement can be quantified through modeled field intensity, focality, and variance at the selected cortical target.; Clinical falsification is possible through cognitive or disease-relevant outcomes in Alzheimer’s patients.
Counter evidence: The supplied clinical prediction is broad: better cognitive or disease-relevant outcomes needs a pre-specified endpoint, effect size, time window, and patient subgroup.; Modeled target engagement alone could remain positive even if the clinical theory fails.
Reasoning tree
Public endorsements
Alois C. Hopf publicly identifies himself as Bottneuro's CSO and co-founder, and his profile describes the company focus as "Clinical-stage Personalized Neuromodulation for CNS Disorders." That is directionally consistent with the theory, but the supplied evidence does not explicitly mention Alzheimer's disease, cortical tES, the left angular gyrus, or memory-network restoration.
Hopf publicly ties himself to Bottneuro's personalized stimulation approach, calling MiaMind "a personalized device, custom made for each patient," and he reportedly co-founded the company to bring his academic findings into clinical use. The broader public record also describes an Innosuisse-backed project on "Personalised transcranial electrical stimulation therapy at home for early-stage Alzheimer's disease." That is consistent with the theory, but the supplied Hopf quotes do not directly state that personalized cortical tES restores memory-network function in Alzheimer's disease, so this is a public mention rather than a clear explicit endorsement of the full causal claim.
Evidence publication IDs: 47610f50-3d57-4923-8415-42fdf4717930
No supplied quote, record, or publication ties Annina Ruffner to a public statement about Bottneuro's theory that personalized cortical tES can restore memory-network function in Alzheimer's disease. The evidence shows company activity and one relevant company publication, but not her public endorsement, mention, or contradiction of that claim.
Bekim Osmani is publicly named as an inventor on a Bottneuro patent covering patient-specific electrostimulation of neuronal tissue. That is direct public evidence that he is associated with the company’s core stimulation approach. The record here does not show him explicitly endorsing the fuller Alzheimer’s-specific claim about restoring memory-network function, and it does not contradict it either.